FirstWord: Drug Combinations: New Rules, New Opportunities

May 5, 2011Media coverage

Biovista featured in FirstWorld’s latest report, “Drug Combinations: New Rules, New Opportunities” For years, drug therapy has been built on that basic equation. Yet as genomic biology sheds light on the astonishing intricacy of disease pathology, it is clear that drugs that combine several compounds must be developed in response.   According to Biovista president … Read More

Biovista Awarded $0.5M to Participate in EC’s Personalized Medicine Initiative

May 5, 2011Media coverage

Article in GEN on Biovista’s participation in the Eurpean “p-medicine” project. Drug repositioning specialist Biovista’s European affiliate has been awarded a $0.5 million grant to fund its participation in the European Commission’s €13.3 million (roughly $19.7 million), four-year p-medicine project focused on developing new tools and virtual physiological human (VPH) models to speed the development … Read More

The Scientist: Teaching an Old Drug New Tricks

April 1, 2011Media coverage

Biotech companies hope to turn the practice of finding novel uses for existing compounds into big business. Andreas and Aris Persidis love to tackle big problems. As graduate students in the 1980s, the two brothers—a naval architect and a biochemist, respectively—would spend long nights knocking around ideas for how to engineer a better propeller or … Read More

Biovista – a Dedicated Approach to Drug Repositioning

December 20, 2010Media coverage

Seeking Alpha’s Jason Chew writes about Biovista’s Drug Repositioning approach: Following up my previous piece on drug repositioning by Orexigen with its diet pill, Contrave, I spoke with Dr. Aris Persidis, President and co-founder of Biovista- a leading company in the drug repositioning business. Drug repositioning is the discovery and development of novel indications for … Read More

Bioworld: Biovista AI boosts Drug Discovery

December 12, 2010Media coverage

BioVista’s Artificial Intelligence Platform Boosts Drug Discovery BioVista has eight ongoing projects that involve using its technology to provide discovery, repositioning, adverse event profiling, patient stratification and other services for partners…BioVista said partnering discussions are ongoing for BVA-201 and BVA-601, but the company has not yet determined how far into preclinical and possibly clinical studies … Read More